FINAL HOURS: 19.98% OFF SITEWIDE

Hi ,

 

Happy (belated) International Women's Day! 

 

We hope you found some time on March 8th to celebrate your strength, beauty, resilience, softness and sensuality in whatever way felt nourishing to you.

 

If you didn't, it's certainly not too late. It's also not too late to shop our International Women's Day sale. You can still get your favorite Foria formulas for 19.98% off, no code needed. But hurry, today's the last day.

 

We chose 19.98% off to highlight Dr. Helen O'Connell, an Australian urologist whose work revealed the true structure of the clitoris for the first time in 1998.

 

Her discoveries confirmed what people with female bodies have known for a long time. About 80% of people with female sexual organs need direct clitoral stimulation to climax. That is simply a biological reality, and thankfully more of us are becoming more aware of it.

 

For too long, many people believed that penetration alone "should" be enough for orgasm to happen, which may be a key reason the pleasure gap still exists. Helping close that gap is exactly why Foria's Intimacy Collection exists.

 

So whether you want to join us in helping close the orgasm gap, or you simply want to save on your favorite Foria formulas, we hope you had a wonderful International Women's Day and continue celebrating all month long.

 

Yours in health, happiness, and closing the pleasure gap,

 

The Foria Team

 

P.S. Today's the last day to shop 19.98% off for International Women's Day! 

You received this email from FORIA. If you would like to unsubscribe, click here.

Silver paying 20% dividend. Plus 68% share gains

A rare silver investment combining growth and monthly income.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Read Online Hi, Tim Plaehn here. Silver has become one of the best investments for both growth AND income. I've just found one tiny fund that is now delivering up to 20% in annualized cash distributions…. And could deliver $1,170 every month for you. However that's not all…. The share price has jumped 68% in just 5 months. This is one of the rarest combinations I've seen in 20 years of analyzing investments. Click here to see how this works. But hurry: the next monthly payout hits soon. To your income, Tim Plaehn Lead Income Strategist P.S. This isn't physical silver. It's a simple ETF that trades like any stock. Buy once, collect monthly income. Monday's Exclusive Content Opendoor Pops After Earnings, But the Big Question Hasn't Changed Reported by Chris Markoch. Published: 2/22/2026. Key Points Opendoor beat revenue expectations but posted a larger-than-expected loss, highlighting ongoing profitability challenges. The company’s “Opendoor 2.0” strategy focuses on faster inventory turns, AI-driven pricing, and breakeven adjusted net income by 2026. Institutional sentiment and sector rotation will likely determine whether OPEN stock can sustain momentum. Special Report: An AI just scored 357 stocks. Here's what it found. (From TradingTips) Stock analysis is frequently peppered with sports metaphors, and with good reason; they fit. That's the case with Opendoor Technologies Inc. (NASDAQ: OPEN). The company reported its Q4 2025 earnings after the market closed, and the results were mixed — yet investors pushed OPEN stock up 14% in after-hours trading. An empty bottle of Coca-Cola (Ad) Is this investing's biggest secret? LeBron James... Michael Phelps... Ted Williams... what connects these sporting legends to the likes of massive companies like Nvidia... Coca-Cola... Geico? And how could that connection help you transform the way you invest? Find out here. Why did Buffett really step down? The theme of the earnings report (branded as an Open House) was: Opendoor 2.0 Does What It Said It Would Do — delivering acquisition growth, faster inventory turns, and stronger cohorts. It outlined the company's progress on a four-step plan to transform the business with an eye toward three goals: To reach breakeven Adjusted Net Income by the end of 2026 on a 12-month go-forward basis To drive positive unit economics while increasing transaction velocity To transition to direct-to-consumer relationships and expand its product suite The report was encouraging, but progress is a relative term. This remains an unprofitable company with relatively modest revenue. In that vein, this report feels like surviving the first quarter of a four-quarter game: you can't win the game in the first quarter, but you can lose it. Opendoor hasn't lost — but what does winning look like? Mixed Earnings Won't Move the Needle Much On the top line, Opendoor reported revenue of $736 million, beating expectations of $591.75 million. However, adjusted earnings per share (EPS) came in worse than expected: a loss of $1.26 versus an expected loss of $0.08. Both revenue and EPS were also sharply lower on a year-over-year (YOY) basis. As a one-off data point that's not devastating — the company made a C-suite change and needs time for a turnaround — but bulls will note the YOY revenue miss was less severe than feared. Call that a point for Opendoor. The Business Model Has a Proven Achilles Heel Opendoor went public in 2020, during the meme-stock craze, and the timing proved to be a double-edged sword. The iBuyer was supposed to reshape how homes are bought and sold. The company's core value proposition is liquidity and convenience: make instant cash offers to homeowners who want to sell quickly without listing, showings, or uncertain timelines, then resell swiftly—the speed of resale drives growth. That engine has always been powered by algorithmic pricing models that decide what to pay sellers, how to price for resale, and which markets to target. While they may not have used AI originally, they are using it now as part of the turnaround strategy to improve efficiency. The problem is the same as with any model: the output is only as good as the historical data it's trained on. If market conditions shift faster than the model adapts, the company can be left holding depreciating inventory. That happened in 2022. Rising interest rates and a rapidly cooling housing market caught the company off guard, leaving inventory bought at much higher prices and forcing massive losses; the stock fell from over $12 at the start of the year to under $1 by year-end. The refrain from retail investors is often "this time it's different." That's a dangerous line of thinking. Interest rates would have to fall significantly to "unfreeze" the housing market, and recent Fed minutes suggest that's unlikely. The takeaway for investors is caution. AI can help, but it's only as effective as the underlying market. Opendoor went public in an unprecedented housing bull market; it survived the downturn, but what does a new equilibrium look like? That's why they keep playing the game. And Opendoor's earnings have allowed it to stay in play. How Should Retail Investors View OPEN Stock? To help answer that question, note that the gains of over 200% in the last 12 months were aided by strong institutional buying in the third and fourth quarters of last year. However, that buying seemed to wane as the year ended. Short interest rose, indicating that larger investors viewed the stock as overextended. That remained the case into 2026, and OPEN was down just over 20% before the earnings report. The takeaway is that OPEN will likely need renewed institutional interest to sustain further gains. But with evidence of broader sector rotation away from tech stocks, there may be less appetite for a company that delivered a good but not great report. Opendoor is a speculative investment and a company still trying to prove its business model at scale. There's time on the clock, but investors will need patience and conviction.       Update your email preferences or unsubscribe here © 2026 American Market News 345 N Reid Place #620 Sioux Falls, SD 57103, United States Terms of Service

We’re Locked In Now: See Why (BIAF) Just Landed On Tomorrow’s Radar

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Krypton Street Just Locked In (Nasdaq: BIAF) For Tomorrow's Watchlist—Tuesday, March 10, 2026 Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Full Coverage On (BIAF) Will Kick Off Early Take A Look At (BIAF) Before Tomorrow Morning… March 9, 2026 We're Locked In Now | See Why (BIAF) Just Landed On Tomorrow's Radar Dear Reader, Here at Krypton Street, we pay close attention to companies aligned with major shifts that have the potential to pull in fast-moving market interest. One of those shifts is taking shape right now in lung cancer screening, where noninvasive diagnostic technology is beginning to change how physicians approach one of the most challenging calls in medicine. For years, patients with suspicious lung nodules have often been left navigating repeat scans, prolonged uncertainty, or invasive procedures that later show no cancer was present. That landscape is beginning to change as more advanced diagnostic tools move from the lab into clinical settings, giving doctors a more data-driven way to assess risk earlier in the process. As the potential for momentum builds behind this transition, companies bringing practical solutions to the front lines of care are starting to command closer attention. bioAffinity Technologies, Inc. (Nasdaq: BIAF) is one of the companies working within this shift, using flow cytometry and proprietary analysis to support the detection of early-stage malignancy. And that is exactly why (BIAF) just earned a spot on my radar and is set to top my watchlist tomorrow morning—Tuesday, March 10, 2026. But keep in mind, (BIAF) has less than 5M shares listed as available to the public, according to MarketWatch. When companies have small public floats like this, the potential exists for big moves if demand begins to shift. This is already starting to show on the chart. (BIAF) recently made an approximate 90% move in under two weeks, from around $.73 on February 6 to $1.39 on February 19, according to data available from Barchart. While traditional methods often lead to invasive procedures for benign findings, the company is advancing a science-based alternative designed to improve decision-making in lung cancer diagnostics. And the deeper you look into what (BIAF) is building, the easier it becomes to see why this company is starting to draw attention. See the company's latest corporate presentation here. Here's a closer look at the technology, clinical utility, and real-world factors that are putting (BIAF) on our radar. Transforming Early Detection bioAffinity Technologies, Inc. (Nasdaq: BIAF) is a biotechnology company focused on the noninvasive diagnosis of early-stage cancer and other diseases of the lung. The company's flagship product, CyPath® Lung, addresses a critical gap in the current healthcare system: the high rate of false positives in lung cancer screening. When a low-dose computed tomography (LDCT) scan identifies a suspicious pulmonary nodule, physicians are often forced to choose between "watchful waiting" or aggressive, invasive biopsies. CyPath® Lung changes this dynamic by analyzing a patient's sputum (phlegm) to identify cell populations indicative of cancer. The test is currently marketed as a Laboratory Developed Test (LDT) through the company's subsidiary, Precision Pathology Laboratory Services. This facility recently maintained its prestigious College of American Pathologists (CAP) accreditation, which is considered the gold standard for laboratory excellence and accuracy. By providing a 92% sensitivity and 87% specificity for detecting cancer in nodules smaller than 2 centimeters, (BIAF) is delivering a high-accuracy tool that helps physicians rule out cancer without surgery. The $10.4B Market The U.S. lung cancer diagnostics market is projected to more than double within the next decade to reach $10.4B by 2034. This projected growth is being driven in part by a rising emphasis on early detection, as lung cancer remains the leading cause of cancer-related death worldwide. Current screening guidelines recommend annual LDCT scans for millions of high-risk individuals, yet uncertainty around scan results continues to create a significant diagnostic burden for both patients and physicians. bioAffinity Technologies, Inc. (Nasdaq: BIAF) is developing CyPath® Lung to address this challenge by providing additional clinical data after a suspicious nodule is identified. In recent case material, the test supported a conservative surveillance strategy for an elderly patient with a suspicious nodule. A later follow-up scan showed that the nodule had resolved, supporting the decision to avoid an invasive and costly biopsy. The ability to help rule out cancer with a high degree of confidence could become an important point of differentiation in a field where false positives often lead to unnecessary medical intervention. Platform Versatility: From Oncology to Asthma Beyond its core lung cancer application, (BIAF) is proving that its flow cytometry platform has broad-spectrum potential. On March 3, 2026, the company presented positive research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The data demonstrated the technology's ability to identify specific antibody receptors in sputum for leading asthma therapies, including dupilumab and benralizumab. This breakthrough suggests that the (BIAF) platform can be used to identify optimal therapies for the approximately 650M children and adults globally suffering from asthma and COPD. By matching patients with the most effective biologic therapies and monitoring inflammatory changes over time, (BIAF) is opening a new vertical in personalized medicine. This diversification reduces reliance on a single diagnostic area and positions the company as a leader in respiratory health technology. Recent Operational Achievements Operational achievements point toward increased accessibility and commercial scale. The company recently announced a validation study with Brooke Army Medical Center (BAMC) to expand sample collection options. By validating deep suction collection alongside spontaneous cough samples, (BIAF) could significantly accelerate the adoption of CyPath® Lung in clinical settings where patients may struggle to produce a sample naturally. Results from this study are expected by mid-year 2026. Furthermore, the company's financial results for the third quarter of 2025 showcased a strategic pivot. While total revenues were $1.4M, the company reported a 122% year-over-year increase in CyPath® Lung testing revenue. This growth was driven by higher case volumes and increased adoption within the Veterans Administration (VA) health system. The company also significantly improved its balance sheet, ending the period with $7.7M in ca-sh, up from $1.1M at the end of 2024. Management and Advisory Strength The leadership team at (BIAF) is led by Maria Zannes, a veteran executive with over 30 years of experience. She has built a team of award-winning scientists, including Chief Science Officer Dr. William Bauta, a medicinal chemist with 25 years of experience in dr-ug discovery and FDA approvals. To further guide its commercial strategy, the company recently appointed nationally recognized authorities to its Medical and Scientific Advisory Board, including specialists from MD Anderson Cancer Center and NYU Grossman School of Medicine. These experts provide independent guidance on clinical priorities and help drive the integration of CyPath® Lung into the standard of care. 7 Reasons Why (BIAF) Will Be Topping Our Watchlist Tomorrow Morning—Tuesday, March 10, 2026… 1. Growing Market: Industry projections indicate the U.S. lung cancer diagnostics market is expected to more than double to about $10.4B by 2034, placing (BIAF) within a rapidly expanding segment of healthcare diagnostics. 2. Small Float: With fewer than 5M shares listed as available to the public, (BIAF)'s small float could have the potential for big moves if demand begins to shift. 3. Recent Momentum: Chart data from Barchart shows that (BIAF) made an approximate 90% move in under two weeks, from about $0.73 on February 6 to $1.39 on February 19. 4. Noninvasive Detection: Through its CyPath® Lung test, (BIAF) is developing a sputum-based method designed to help identify early-stage lung malignancy without the need for invasive diagnostic procedures. 5. High Accuracy: Clinical data cited for CyPath® Lung shows that (BIAF) achieved 92% sensitivity and 87% specificity when detecting cancer in nodules smaller than 2 centimeters. 6. Operational Progress: Recent financial disclosures show that (BIAF) reported a 122% year-over-year increase in CyPath® Lung testing revenue while strengthening its balance sheet with $7.7M in ca-sh at the end of Q3 2025. 7. Platform Expansion: Research presented at the AAAAI Annual Meeting suggests the technology platform developed by (BIAF) may help identify antibody receptor responses related to leading asthma therapies. Take A Look At (BIAF) Before Tomorrow Morning… (BIAF) just hit our radar for several reasons. The company has fewer than 5M shares available to the public, and small floats like this can sometimes have the potential for big moves if demand begins to shift. Recent chart activity already shows signs of momentum, with (BIAF) recently making an approximate 90% move in under two weeks. At the same time, the company is working within a lung cancer diagnostics market that industry projections suggest could more than double to about $10.4B by 2034. Beyond the market backdrop, the underlying technology is what makes this story worth understanding. CyPath® Lung is designed as a noninvasive sputum-based test that helps physicians evaluate suspicious lung nodules without immediately resorting to invasive procedures. Clinical data cited for the test reports 92% sensitivity and 87% specificity when identifying cancer in nodules smaller than 2 centimeters. On top of that, research presented earlier this month suggests the same platform may help identify antibody receptor responses connected to leading asthma therapies. Operational progress is also beginning to appear in the numbers. CyPath® Lung testing revenue increased 122% year-over-year, and the company reported $7.7M in ca-sh at the end of Q3 2025. Expect (BIAF) to be high on our radar tomorrow morning—Tuesday, March 10, 2026. Take a look at (BIAF) before you call it a night, and keep an eye out for my update in the morning. Have a good night. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter   KryptonStreet.com ("KryptonStreet" or "KS" ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/09/2026 and ending on 03/10/2026 to publicly disseminate information about (BIAF:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD ("Funds"). These Funds were part of the seventy seven thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (BIAF:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/biaf-2Xr7H/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | Constant Contact Data Notice Sent by alex@kryptonstreet.com

New Nasdaq Idea (BIAF) Triggers Our Radar Watch Tuesday (Low Float - 5 Potential Catalysts)

In the fast-changing world of medical diagnostics

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored New Nasdaq Idea (BIAF) Triggers Our Radar Watch Tuesday (Low Float - 5 Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* March 9th Greetings, Friend! In the fast-changing world of medical diagnostics, one emerging company is rewriting the playbook for detecting deadly diseases. By developing new noninvasive testing solutions, it’s setting its sights on transforming early lung cancer detection—making it quicker, more precise, and within reach for millions of people. The market for lung cancer diagnostics, worth nearly $20Bn in 2023, is projected to surge to $38Bn by 2034, creating major opp's for innovative technologies with life‑changing impact. Driven by science and focused on catching lung disease early, this company’s approach could reshape how physicians diagnose and manage respiratory conditions. With fewer than 5Mn shares in its float and a string of noteworthy headlines already in 2026, this Nasdaq-listed idea has firmly earned its spot on our radar: bioAffinity Technologies, Inc. (Nasdaq: BIAF) bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. Early Detection of Lung Cancer Saves Lives Screening is an important tool to find lung cancer at the earliest stages and increase survival. The current protocol for screening people at high risk for lung cancer uses low-dose computed tomography (LDCT) to identify nodules in the lungs. But LDCT has a low positive predictive value that can lead to unnecessary invasive procedures. Addressing a critical need to find cancer early and treat cancer specifically, bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Their first product, CyPath® Lung, is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company, as a Laboratory Developed Test. Growing Platform Technology The Company's commercial noninvasive lung cancer test is the first in a pipeline that includes development of companion diagnostics for asthma and chronic obstructive pulmonary disease (COPD) 92% Sensitivity - 87% Specificity 99% - Negative Predictive Value - 88% Accuracy CyPath® Lung shows high sensitivity and specificity in detecting lung cancer in people with small, indeterminate pulmonary nodules Proprietary AI Analysis of Flow Cytometry Data AI-driven algorithm analyzes complex flow cytometric data from patient sputum samples Profiles the lung microenvironment to differentiate between patients with or without lung cancer Patient-friendly / Physician-focused At-home collection (no needles, no blood) with results 3 days after sample arrives at lab CyPath® Lung - Physician-Focused, Patient-Friendly, Reimbursed by Ins. How the CyPath® Lung Test Works Flow cytometry interrogates the lung microenvironment Sputum samples are processed into a single-cell suspension and labelled before data acquisition with antibodies, reagents, labeling agents and TCPP, a synthetic porphyrin taken up by cancer and cancer-related cells Proprietary AI-driven platform analyzes sample for cancer Automated analysis identifies cell populations of interest and eliminates debris, dead cells, and cell aggregates to distinguish between likely cancer and benign conditions Quality control assures the sample is from the lungs Fluorescent antibody specifically identifies lung macrophages to ensure the sample comes from the lungs AI-driven analysis takes only minutes to identify lung cancer Analysis developed by machine learning detects cell populations indicative of lung cancer A Solid Foundation for Growth Revenue Milestones Achieved in 2025 100% increase in year-over-year revenue and units sold Published multiple case studies and physician testimonials on the human impact of CyPath® Lung Entered major VA medical centers with lung nodule programs Phased field expansion in strategic regional markets in Northeast and Southern U.S. Expanded indications for use of CyPath® Lung for surveillance after treatment and detection of metastatic cancer to the lung Longitudinal Clinical Trial Launches in 2026 Longitudinal study supports inclusion of CyPath® Lung as part of the standard of care for pulmonary nodules Clinical study will evaluate CyPath® Lung performance to support risk stratification, clinical decision-making, detection and survivor surveillance 2000-patient longitudinal clinical trial with up to 20 collection sites including more than a dozen VA and military medical centers are qualified and ready Patient enrollment begins Q1 2026 with financial support from the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), a nonpro-fit organization dedicated to advancing military medicine Find Report Source And More Here: BIAF Website. BIAF Presentation. ----- 5 Potential Catalysts Put (Nasdaq: BIAF) In The Spotlight Tuesday. 1.) BIAF Has An Fairly Low Float (Volatility Potential May Be Explosive). Sporting a float of roughly 4.26Mn shares, according to Yahoo Finance, volatility potential could pop up in a flash for BIAF. 2.) bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients. bioAffinity Technologies’ latest research, presented at the AAAAI 2026 annual meeting, highlights a new diagnostic platform capable of identifying key antibody drug receptors in sputum for therapies like dupilumab and benralizumab. This breakthrough can help physicians tailor asthma and COPD treatments more effectively, improving outcomes while reducing trial-and-error approaches. Using a proprietary flow cytometry platform enhanced with automated AI analysis, the company’s technology aims to guide personalized care, monitor disease progression, and advance precision medicine for millions of respiratory patients globally. 3.) bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test. bioAffinity Technologies announced a validation study with Brooke Army Medical Center to expand CyPath® Lung’s diagnostic capabilities by testing sputum samples obtained via deep suction methods. The study, involving 30–50 patients, aims to demonstrate CyPath® Lung’s reliability in diverse clinical settings and enhance its applicability in early lung cancer detection. This collaboration underscores bioAffinity’s commitment to working with medical professionals and leveraging AI-driven technology to improve early diagnosis, save lives, and strengthen adoption of its innovative noninvasive test. 4.) New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer. A new bioAffinity Technologies case study showcased how its CyPath® Lung test helped avoid an invasive biopsy for a 79-year-old patient with a suspicious lung nodule. The test’s negative result enabled a safe, conservative surveillance plan, later validated by follow-up scans showing no malignancy. With 92% sensitivity, 87% specificity, and 88% accuracy for small nodules, CyPath® Lung continues to prove its clinical value. 5.) bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board. bioAffinity Technologies has expanded its Medical and Scientific Advisory Board by appointing three prominent pulmonary and lung cancer specialists: Drs. David Ost, Daniel Sterman, and J. Scott Ferguson. Their expertise will guide the integration of the company’s CyPath® Lung diagnostic test into clinical practice for early lung cancer detection. These appointments highlight bioAffinity’s dedication to clinical excellence and strategic growth. The strengthened board will help advance innovation, enhance adoption of noninvasive diagnostics, and support the company’s mission to improve patient outcomes through early detection. ----- Coverage is underway on bioAffinity Technologies, Inc. (Nasdaq: BIAF). Be on the lookout for updates coming shortly. Talk soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/09/2026 and ending on 03/10/2026 to publicly disseminate information about (BIAF:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the seventy seven thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (BIAF:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/biaf-2xr7h/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice